Sixty healthy subjects ( 39 male , 21 female ; age 20-45 years ) were randomized to receive a single subcutaneous injection of alirocumab 75 mg via 1-mL prefilled pen into the abdomen , upper arm , or thigh ( NCT01785329 ) .